当前位置:产品>信号通路产品>抑制剂>产品详情

PTC124(Ataluren)
Catalog Number: E1KS6003
Amount: 10mg1​ PHYSICAL AND CHEMICAL PROPERTIES
Applications: Reactivity:
产品类型: Unconjugated
发货周期: 现货
说明书:     PDF
总价格:    225.6元
选择数量:

-
+

咨询客服
概述
  • Catalog Number:

    E1KS6003
  • Amount:

    10mg1​ PHYSICAL AND CHEMICAL PROPERTIES

2​ Biological Activity
PTC124 (Ataluren) targets genetic disorders caused by nonsense mutations. [1] PTC124 is an orally bioavailable compound that promotes of the human CFTR-G542X nonsense allele in a CF mouse model. [2] Effectiveness of PTC124 treatment of cystic fibrosis caused by nonsense mutations: a prospective phase II trial. [3] PTC124 induces dose-dependent suppression of premature translational termination without concomitant effects on normal termination or mRNA decay. [1]In safety pharmacology studies in rats and dogs, oral administration of PTC124 induces no adverse neurological, pulmonary, or cardiovascular effects at doses through 1500 mg/kg. In toxicology studies in rats and dogs at oral doses through 1500 mg/kg for 28 days, PTC124 has shown good tolerability. [1] The minimal concentration of PTC124 showing discernable readthrough was 0.01–0.1 mM (2.8–28 ng ml-1), whereas the concentration promoting maximal activity was approximately 3 mM(852 ng ml-1). [1]
3​ References:
[1] Welch EM et al. Nature. 2007 May 3;447(7140):87-91
[2] Ming Du et al.PNAS. 2008 February 12;105(6):2064-2069
[3] Samit Hirawat et al. J Clin Pharmacol. 2007 Apr;47(4):430-44
The pharmacological and toxicological properties of this product have not been fully investigated. Exercise caution in use and handling. This product must not be used in humans.

2​ Biological Activity PTC124 (Ataluren) targets genetic disorders caused by nonsense mutations. [1] PTC124 is an orally bioavailable compound that promotes of the human CFTR-G542X nonsense allele in a CF mouse model. [2] Effectiveness of PTC124 treatment of cystic fibrosis caused by nonsense mutations: a prospective phase II trial. [3] PTC124 induces dose-dependent suppression of premature translational termination without concomitant effects on normal termination or mRNA decay. [1]In safety pharmacology studies in rats and dogs, oral administration of PTC124 induces no adverse neurological, pulmonary, or cardiovascular effects at doses through 1500 mg/kg. In toxicology studies in rats and dogs at oral doses through 1500 mg/kg for 28 days, PTC124 has shown good tolerability. [1] The minimal concentration of PTC124 showing discernable readthrough was 0.01–0.1 mM (2.8–28 ng ml-1), whereas the concentration promoting maximal activity was approximately 3 mM(852 ng ml-1). [1] 3​ References: [1] Welch EM et al. Nature. 2007 May 3;447(7140):87-91 [2] Ming Du et al.PNAS. 2008 February 12;105(6):2064-2069 [3] Samit Hirawat et al. J Clin Pharmacol. 2007 Apr;47(4):430-44 The pharmacological and toxicological properties of this product have not been fully investigated. Exercise caution in use and handling. This product must not be used in humans.

相关推荐

Responsive image
Catalog Number:E1KS1020
Amount:5mg
Reactivity:
Applications:    
Swiss-Prot No.
Price:225.6元
Responsive image
Catalog Number:E1KS2250
Amount:50mg
Reactivity:
Applications:    
Swiss-Prot No.
Price:225.6元
Responsive image
PLX-4720   
Catalog Number:E1KS1152
Amount:5mg
Reactivity:
Applications:    
Swiss-Prot No.
Price:225.6元